Pharma Industry News

Atyr Pharma: Q1 Earnings Snapshot

SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Friday reported a loss of $10.8 million in its first quarter. The San Diego-based company said it had a loss of 11 cents per share. The company's shares closed at 56 cents.

What to Know About This Fund's $50 Million Exit From Ascendis Pharma

On May 14, 2026, Siren disclosed in an SEC filing that it sold its entire holding of Ascendis Pharma A/S (ASND 0.22%), liquidating 235,862 shares in an estimated $52.87 million transaction based on quarterly average pricing. According to a SEC…

Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why

Pfizer (PFE) trades at $25.75 with a rare 6.66% dividend yield and 9x forward P/E, offering upside. Molina and Halliburton join Pfizer as defensive cash generators with structural edges through pricing power and margin stability. This post may…

2 Ways to Play the Big Pharma Patent Cliff

Major pharmaceuticals firms like Pfizer Inc. NYSE: PFE and Novo Nordisk A/S NYSE: NVO have been fighting to spend large sums on smaller companies in the space in recent months (the former of these companies completed an acquisition of weight loss…

Strong biopharma dealmaking market set to continue

Experts believe the dealmaking trend will persist for several years, even into new therapeutic areas and earlier-stage assets. Experts state concerns like inflation, oil prices, and war have not slowed dealmaking, unlike past events such as the…

Hertfordshire Pharma lands £2.3m Saudi contracts after UKEF steps in to plug working capital gap

That is precisely the bind that Masters Speciality Pharma, a 41-year-old Hertfordshire specialist pharmaceutical company, found itself in last year after winning two sizeable orders from Saudi Arabia worth a combined £2.3 million. The remedy…

Olema Stock: The Market Overreacted To Roche's SERD Failure (NASDAQ:OLMA)

Olema Pharmaceuticals is rated a cautious buy, with upside potential tied to pivotal OPERA-01 Phase 3 trial results expected in fall 2026. Palazestrant differentiates itself as a CERAN with superior mechanistic action, favorable pharmacokinetics…

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next blockbusters. Bristol's deal is unique because…

American Century Small Cap Value Fund Q1 2026 Commentary (Mutual Fund:ASVIX)

The fund's significant overweight in energy, particularly holdings like Crescent Energy, Permian Resources, and Magnolia Oil & Gas, contributed positively as oil prices surged due to Middle East conflict. ASVIX remains underweight health care…

105,950 Orion Corporation A shares converted into B shares

STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 105,950 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 105,950…

Call Them Gamblers or Investors, They're Moving Stocks

Q4 Results 15th May Live: Tata Steel, PowerGrid, Solar, SAIL, Hindustan Copper, Premier Energies, Cochin Shipyard, Godrej, Godfrey Phillips, ITC Hotels, Gland Pharma, SJVN to announce Q4 results, TMPV, HAL, JSW Steel, Apollo Tyres, VMM in focus

Q4 Results Today, May 15, 2026 Live Updates: Find all the latest Q4 results 2026 updates of Aarti Drugs, Aether Industries, Abans Financial Services, Ashapura Intimates Fashion, AKI India, Alacrity Securities, Amber Enterprises India, Alembic…

Paysign PAYS Q1 2026 Earnings Call Transcript

Tuesday, May 12, 2026 at 5 p.m. ET President and Chief Executive Officer — Mark R. Newcomer Chief Financial Officer — Jeffery Baker President, Patient Affordability — Matthew Turner Chief Payments Officer — Matthew…

'Irrational': Judge erupts as Cosette shirks Mayne's $13m legal bill

The courtroom stoush between jilted takeover target Mayne Pharma and its former US suitor, Cosette, has turned even uglier after a judge slammed the American medical giant for making irrational, radical, and counterintuitive arguments about why it…

Purpose and Practice: Transforming Health Brands for the Modern Consumer

The future of brands gets decided here. Join the industry's top marketers at Brandweek for the ideas, insights, and connections shaping what's next. Get your ticket. In this episode of Adspeak by ADWEEK, chief brand and community officer Jenny…